Caladrius Biosciences, Inc. , a clinical-stage biopharmaceutical company dedicated to the development of innovative therapies designed to treat or reverse disease, provides a business update and. | March 22, 2022
Analysts expect that Caladrius Biosciences, Inc. (NASDAQ:CLBS – Get Rating) will announce ($0.15) earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Caladrius Biosciences’ earnings. The lowest EPS estimate is ($0.16) and the highest is ($0.13). Caladrius Biosciences posted earnings per share of ($0.28) […]
11.03.2022 - Currently Enrolling Clinical Trials with Lomecel-B in Three Disease Indications: Hypoplastic Left Heart Syndrome (Phase 2a), Alzheimer’s Disease (Phase 2a), and Covid-related Acute Respiratory Distress Syndrome (Phase 1) Lomecel-B for HLHS .
/PRNewswire/ The cell therapy market is poised to grow by USD 21.061 billion from 2021 to 2026, progressing at a CAGR of 56.79% during the forecast period,.
Blue Planet Investment Trust Plc - Half-year Report to October 2021 PR Newswire London, December 15 Blue Planet Investment Trust plc Half Year Report and Accounts For